SARS-CoV-2-CZ-PREVAL-II Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 7,268
- 试验地点
- 1
- 主要终点
- Detection of a number of subjects with IgG anti-SARS-CoV-2 antibodies
研究概览
简要总结
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
详细描述
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in four specific cohorts: participants with chronic illness, healthy volunteers participating in the Study of the Czech Academy of Science, healthcare workers, and healthy volunteers that participated in the "Herd Immunity Study SARS-CoV-2-CZ-Preval" in May 2020.
The primary aim of the study is to estimate the number of people with anti-SARS-CoV-2-antibodies, i.e., people with COVID-19 history, or with vaccination against COVID-19.
Antibodies test will focus on two main proteins of virus SARS-CoV-2: S-protein and N-protein.
The secondary aims of the study are:
- quantitative analysis of cellular immunity and the other relevant markers,
- estimation of the proportion of participants with asymptomatic COVID-19 infection
- quantification of anti-SARS-CoV-2 antibodies and cell immunity according to individual risk factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •signed Informed consent
- •willingness to complete the study questionnaire
- •demographic criteria - age 18 years old and more
- •clinical criteria - without acute health problems
- •time criteria - sample collection in the defined period time
排除标准
- 未提供
结局指标
主要结局
Detection of a number of subjects with IgG anti-SARS-CoV-2 antibodies
时间窗: September-October 2021
The primary outcome is to quantify the prevalence of participants with IgG anti-SARS-CoV-2 antibodies in the specified subjects cohorts.
次要结局
未报告次要终点